The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.
September 23rd 2024
The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer
February 20th 2020Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.
If Only That Phase III Oncology Trial Had Been Designed Differently
February 19th 2020The cancer treatment community's ultimate perception of a successfully completed phase III randomized trial depends in large part on how well the trial was conceived and structured. To permit adequate accrual in a timely manner and optimize the chances for a study to achieve success, the question it poses must be relevant to ensure interest by clinical investigators, referring clinicians, and potential research subjects. Further, the initiative must have adequate funding for data collection and analysis, translational laboratory investigations, and other trial components.
Dr. Wenham on Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer
February 19th 2020Robert M. Wenham, MD, gynecologic oncologist and chair of the Department of Gynecologic Oncology at Moffitt Cancer Center, sheds light on the debate between neoadjuvant chemotherapy and primary debulking surgery in patients with newly diagnosed, advanced ovarian cancer.
Targeted Therapy, Immunotherapy Are Replacing Chemotherapy in Endometrial Cancer
Researchers and practicing physicians have done as much as possible with chemotherapy as a systemic treatment for endometrial cancers, and other modalities—alone and in combination—are likely to become standard of care in the coming years, Shannon N. Westin, MD, MPH, said during a presentation at the 2020 SGO Winter Meeting.
Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer
Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.
Dr. Coleman on the Use of Veliparib in Ovarian Cancer
January 29th 2020Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.
Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer
January 29th 2020Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.
Dr. Duska on the Utility of the Fagotti Score in Advanced Ovarian Cancer
January 29th 2020Linda R. Duska, MD, professor of obstetrics and gynecology and gynecologic oncologist at the University of Virginia, explains whether the Fagotti score provides an accurate assessment of whether a patient with newly diagnosed, advanced ovarian cancer can achieve a complete resection in surgery.